Pre-emptive azacitidine for relapse prevention in acute myeloid leukaemia
Mené sur 26 patients atteints d'un syndrome myélodysplasique de stade avancé et sur 172 patients atteints d'une leucémie myéloïde aiguë à haut risque de récidive, cet essai de phase II évalue l'efficacité, du point de vue de la proportion de patients ne connaissant pas de récidive 6 mois après le début du traitement, et la toxicité de l'azacitidine dispensée en traitement préventif de la récidive
Residual disease after apparently successful therapy as evaluated by conventional techniques accounts for the vast majority of relapses in patients with cancer and is readily detectable in patients diagnosed with acute leukaemia. The bone marrow origin of these cancers allows easy access to even minimal populations of tumour cells in the bone marrow and peripheral blood (minimal residual disease). However, in tumours originating outside the bone marrow, the proportion of residual cells in these tissues is much lower, and cell-free liquid biopsy technologies are needed to detect minimal residual disease
The Lancet Oncology , commentaire, 2017